You're contacting media contact of this press release

Title: Next-Generation Japanese GLP-1 weight loss pills: Seeking North American Distributors

Japan, 12th Mar 2026 - Asa Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo; CEO: Tomoko Iwase), a manufacturer and distributor of health foods, has launched North American expansion of a next-generation diet supplement utilizing proprietary carbonated granule technology, targeting the rapidly growing global “GLP-1 (appetite-suppressing hormone)” support market. In conjunction with this launch, the company has formally begun inviting applications from strategic partners (distributors), including clinics, fitness chains, and luxury spas.In the United States, GLP-1 receptor agonists such as Mounjaro have attracted significant attention. However, challenges remain, including high costs, resistance to injections, and concerns regarding side effects.The product offered by Asa Pharmaceutical Co., Ltd. adopts the functional ingredient “Metaboloid (lemon verbena + hibiscus),” which is supported by scientific evidence and promotes natural GLP-1 secretion. In addition, by combining Japan-originated carbonated granule technology with aroma effects, the supplement enables sustainable weight management without excessive burden. Four Added Values for U.S. Distribution Partners1. Clinically Supported Evidence for Promoting GLP-1 SecretionFormulated with “Metaboloid,” recognized as the most innovative ingredient at the NutraIngredients Award in Europe. Clinical trials confirmed increased GLP-1 secretion after intake and a 64% improvement in appetite suppression scores. The product can be presented with confidence to evidence-oriented, high-income consumers in the United States.2. Carbonated Granule Technology Delivering Visual and Sensory SatietyThe unique texture of carbonated granules that effervesce in the mouth provides not only a refreshing sensation but also expands i...

This press release is issued by King Newswire